Barclays analyst Carter Gould raised the firm’s price target on Biogen to $313 from $275 and keeps an Equal Weight rating on the shares. There are some points for debate "around the edges," but full data presentation of the lecanemab Clarity AD study "should further de-risk approval," Gould tells investors in a research note. The analyst says investor focus is likely to shift toward commercial aspects going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- MRNA, BIIB, or IQV: Which Biotech Stock Earns the Street’s “Strong Buy” Rating?
- Biogen and Eisai’s Alzheimer’s Drug May Pose Serious Risks, Say Researchers
- Piper keeps lecanemab thesis after full data presentation
- Eisai and Biogen present full results for Lecanemab phase 3 study in AD
- Prothena data from AD/PD abstract ‘promising,’ says Jefferies